NEW YORK (GenomeWeb) – Luminex announced today that it has agreed to acquire MilliporeSigma's flow cytometry portfolio for $75 million, consisting of about $69.9 million to be paid under a stock and asset purchase agreement and about $5.1 million in committed inventory purchases.

Austin, Texas-based Luminex anticipates that the deal will close by the end of 2018 and could contribute between $40 million and $50 million to its revenues in 2019.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.